证券日报网讯1月23日，泰和科技（300801）在互动平台回答投资者提问时表示，泰和科技碳酸亚乙烯 酯(VC)项目的新增设备已经到位，正在改造中，预计春节前后可以完成改造。 ...

每经AI快讯，有投资者在投资者互动平台提问：目前VC装置改造进展怎样了？ 泰和科技（300801.SZ）1月23日在投资者互动平台表示，泰和科技碳酸亚乙烯酯（VC）项目的新增设 备已经到位，正在改造中，预计春节前后可以完成改造。 （文章来源：每日经济新闻） ...

Group 1 - The acrylic acid concept increased by 2.64%, ranking third among concept sectors, with 13 stocks rising, including Hongqiang Co., which hit the daily limit, and Bohai Chemical, Taihe Technology, and Satellite Chemical, which rose by 7.56%, 6.71%, and 6.67% respectively [1] - The acrylic acid sector saw a net inflow of 329 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Wanhua Chemical with a net inflow of 174 million yuan [2] - The top stocks by net inflow ratio included Hongqiang Co., ST Shenhua, and Daoshengtian, with net inflow ratios of 42.22%, 11.79%, and 5.01% respectively [3] Group 2 - The top performers in the acrylic acid sector included Wanhua Chemical with a 4.39% increase, Tianlong Group with a 6.04% increase, and Hongqiang Co. with a 10.00% increase [3] - The stocks with the largest declines included Guoen Co. with a decrease of 2.04%, Brother Technology with a decrease of 0.87%, and Akoli with a decrease of 0.61% [4] - The trading volume and turnover rates varied, with Hongqiang Co. having a turnover rate of 10.78% and Tianlong Group at 26.90% [3][4]

Core Viewpoint - Taihe Technology (300801) clarified that its brainwave biofeedback device is not part of the company's main business and is currently not on the market, being in the performance and appearance optimization stage, which does not significantly impact the company's operating performance [1] Summary by Relevant Categories - **Product Development** - The brainwave biofeedback device is still in the optimization phase and has not been launched in the market [1] - **Business Impact** - The project does not have a significant impact on the company's operating performance at this stage [1] - **Investor Communication** - The company encourages investors to pay attention to regular announcements for updates on the project [1]

Group 1 - The core point of the article is that Taihe Technology (300801) has a total of 29,361 shareholders as of January 9, 2026 [1]

Group 1 - The core viewpoint of the news is that Taihe Technology has shown significant stock performance and financial growth, with a notable increase in revenue and net profit year-over-year [1][2]. - As of January 8, Taihe Technology's stock price increased by 14.59% year-to-date, with a 12.79% rise over the last five trading days and a 22.00% increase over the last 60 days [1]. - The company reported a revenue of 2.12 billion yuan for the period from January to September 2025, representing a year-on-year growth of 27.73%, and a net profit of 88.77 million yuan, up 5.99% year-on-year [2]. Group 2 - Taihe Technology has a market capitalization of 6.915 billion yuan, with a trading volume of 268 million yuan and a turnover rate of 6.31% as of January 8 [1]. - The company has a diverse revenue structure, with 76.35% of its income coming from water treatment agents and 23.10% from chlor-alkali products [1]. - Since its A-share listing, Taihe Technology has distributed a total of 375 million yuan in dividends, with 174 million yuan distributed over the past three years [3].

Group 1 - The core viewpoint of the article is that Taihe Technology's brainwave biofeedback device is currently based on classical algorithms and has not yet adopted deep learning or AI technologies [1] - The technology is still in the internal performance testing and appearance design optimization phase and has not been launched in the market [1]

Core Viewpoint - Taihe Technology (300801) is currently improving the performance and appearance of its brainwave biofeedback device, which has not yet entered mass production and is not accepting orders, indicating a need for caution regarding investment risks [1]. Group 1 - The brainwave biofeedback device developed by Taihe Technology is undergoing continuous improvements [1]. - The device has not yet reached the stage of mass production [1]. - Taihe Technology is currently unable to accept orders for the device [1].

Core Viewpoint - The company is currently improving the performance and appearance of its brainwave biofeedback device, which has not yet entered mass production and is not accepting orders [1] Group 1 - The brainwave biofeedback device is under continuous development [1] - The company has not started mass production of the device [1] - Orders for the device are not being accepted at this time [1]

泰和科技（300801.SZ）1月6日在投资者互动平台表示，泰和科技研发的脑波生物反馈装置的性能和外 观在持续地改进中，尚未批量生产，还不能接受订单，请注意投资风险。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问公司脑机相关产品是否已经商用？有没有订单产 生？ ...